Logo

Galapagos Division to Make Cell-based Assays for Dart Drug Program

Dec 09, 2008
NEW YORK (GenomeWeb News) – Galapagos’ service division, BioFocus DPI, will make cell-based assays for Dart Neuroscience, which will use them in its drug discovery programs for brain disorders, Galapagos said today.
 
The three-year collaboration is potentially worth €4.1 million ($5.4 million) to Galapagos, the Mechelen, Belgium-based firm said.
 
In addition to providing the assays, BioFocus will perform high-throughput screening and hit expansion using its compound collections. It also will provide compound management for Dart over the three-year period.
 
San Diego-based Dart is privately held and was founded earlier this year.

Breaking News
The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.